- $3.44bn
- $6.50bn
- $4.37bn
- 56
- 87
- 81
- 88
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 8.22 | ||
PEG Ratio (f) | 0.11 | ||
EPS Growth (f) | 276.02% | ||
Dividend Yield (f) | 4.65% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.8 | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | 14.07 | ||
Price to Sales | 0.79 | ||
EV to EBITDA | 15.04 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 1.23% | ||
Return on Equity | -3.54% | ||
Operating Margin | 2.43% |
Financial Summary
Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 4,088.2 | 4,138.7 | 4,451.6 | 4,655.6 | 4,373.4 | 4,435.65 | 4,536.06 | 2.48% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | -68 | -68.66 | n/a | n/a | n/a | n/a | +8.33 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
Directors
- Rolf Classon NEC (76)
- Murray Kessler PRE (61)
- Raymond Silcock CFO (71)
- Robert Willis CHO (52)
- Thomas Farrington EVP (63)
- Todd Kingma EVP (61)
- Svend Andersen EVP (59)
- James Dillard EVP (57)
- Ronald Janish EVP (55)
- Sharon Kochan EVP (53)
- Grainne Quinn EVP (51)
- Bradley Alford IND (64)
- Orlando Ashford IND (52)
- Katherine Doyle IND (53)
- Adriana Karaboutis IND (58)
- Jeffrey Kindler IND (64)
- Erica Mann IND (62)
- Donal O'Connor IND (70)
- Geoffrey Parker IND (56)
- Theodore Samuels IND (66)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 28th, 2013
- Public Since
- December 17th, 1991
- No. of Shareholders
- 4,088
- No. of Employees
- 8,379
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
New York Stock Exchange
- Shares in Issue
- 136,458,620

- Address
- The Sharp Building, DUBLIN, D02 TY74
- Web
- https://www.perrigo.com/
- Phone
- +353 17094000
- Contact
- Bradley Joseph
- Auditors
- Ernst & Young LLP
Latest News for PRGO
Upcoming Events for PRGO
Perrigo Company PLC Annual Shareholders Meeting
Perrigo Company PLC Annual Shareholders Meeting
Q1 2025 Perrigo Company PLC Earnings Call
Q1 2025 Perrigo Company PLC Earnings Release
Q2 2025 Perrigo Company PLC Earnings Release
Similar to PRGO
Abbvie
New York Stock Exchange
Bausch Health Companies
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Cardinal Health
New York Stock Exchange
FAQ
As of Today at 22:37 UTC, shares in Perrigo are trading at $25.22. This share price information is delayed by 15 minutes.
Shares in Perrigo last closed at $25.22 and the price had moved by -19.35% over the past 365 days. In terms of relative price strength the Perrigo share price has underperformed the S&P500 Index by -25.56% over the past year.
The overall consensus recommendation for Perrigo is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Perrigo dividend yield is 7.64% based on the trailing twelve month period.
Last year, Perrigo paid a total dividend of $1.93, and it currently has a trailing dividend yield of 7.64%. We do not have any data on when Perrigo is to next pay dividends.
We do not have data on when Perrigo is to next pay dividends. The historic dividend yield on Perrigo shares is currently 7.64%.
To buy shares in Perrigo you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $25.22, shares in Perrigo had a market capitalisation of $3.44bn.
Here are the trading details for Perrigo:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: PRGO
Based on an overall assessment of its quality, value and momentum Perrigo is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Perrigo is $34.50. That is 36.8% above the last closing price of $25.22.
Analysts covering Perrigo currently have a consensus Earnings Per Share (EPS) forecast of $2.99 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Perrigo. Over the past six months, its share price has outperformed the S&P500 Index by +5.95%.
As of the last closing price of $25.22, shares in Perrigo were trading -4.87% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Perrigo PE ratio based on its reported earnings over the past 12 months is 8.22. The shares last closed at $25.22.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Perrigo's management team is headed by:
- Rolf Classon - NEC
- Murray Kessler - PRE
- Raymond Silcock - CFO
- Robert Willis - CHO
- Thomas Farrington - EVP
- Todd Kingma - EVP
- Svend Andersen - EVP
- James Dillard - EVP
- Ronald Janish - EVP
- Sharon Kochan - EVP
- Grainne Quinn - EVP
- Bradley Alford - IND
- Orlando Ashford - IND
- Katherine Doyle - IND
- Adriana Karaboutis - IND
- Jeffrey Kindler - IND
- Erica Mann - IND
- Donal O'Connor - IND
- Geoffrey Parker - IND
- Theodore Samuels - IND